Increased <scp> <i>MYBL2</i> </scp> expression in aggressive hormone‐sensitive prostate cancer
Yuki Yoshikawa(Memorial Sloan Kettering Cancer Center), Christopher J. Sweeney(Dana-Farber Cancer Institute), Elai Davicioni(Coherus BioSciences (United States)), Glenn Liu(University of Wisconsin Carbone Cancer Center), Haruhito Azuma(Osaka Medical and Pharmaceutical University), Goutam Chakraborty(National Centre for Cell Science), Gwo‐Shu Mary Lee(Dana-Farber Cancer Institute), David A. Frank(Brigham and Women's Hospital), Ying Z. Mazzu(Memorial Sloan Kettering Cancer Center), Konrad H. Stopsack(Memorial Sloan Kettering Cancer Center), Foster Burton(Dana-Farber Cancer Institute), Philip W. Kantoff(Dana-Farber Brigham Cancer Center), Subhiksha Nandakumar(Memorial Sloan Kettering Cancer Center), Sai Harisha Rajanala(Memorial Sloan Kettering Cancer Center), Victoria Wang(Dana-Farber Cancer Institute), Michael A. Carducci(Johns Hopkins University), Yu‐Hui Chen(Dana-Farber Cancer Institute), Rahim Hirani(New York Medical College)
Cited by 17
Related Papers
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
|New England Journal of Medicine|2010|5.5k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Gene expression correlates of clinical prostate cancer behavior
|Cancer Cell|2002|2.5k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
|Journal of Clinical Oncology|2018|1.1k